Matches in Nanopublications for { ?s ?p "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_provenance.
- NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP486381.RAHdX1mPlSTmwIj8y_TAOR6OpR1PUMh8AmZcXMmpM1GEQ130_provenance.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_provenance.